Artelo Biosciences, Inc.

Snapshot

Artelo is a pre-revenue clinical-stage biotech with no products on the market. FY 2025 net loss was $12.9M with no revenue, and cash of $4.2M barely covers a few months of its $8.5M annual cash burn.

What's Happening Right Now

• Mon 26th Oct '26 · Conference: Artelo will present data on its FABP5 inhibitor ART26.12 at the IASP 2026 World Congress on Pain (Oct 26-30) and plans a Phase 1 multiple ascending dose study in Q4 2026; no new clinical data was disclosed.
• Fri 9th Oct '26 · Delisting risk: On Oct 9, 2026, Artelo disclosed via 8-K that it is among roughly 180 Nasdaq companies below the SEC's new $5 million market-value listing threshold, which could trigger delisting proceedings if the rule takes effect.
• Wed 7th Oct '26 · Conference: Artelo was selected for its first company presentation at BIO-Europe 2026 (Nov 10) to recap ART26.12 data as a partnering pitch; no new data or deal was announced.
• Wed 23rd Sep '26 · Patent filing: On Sep 23, 2026, Artelo filed a provisional patent for ART27.13 in obesity after obese mice lost ~20% body weight alone and ~40% combined with semaglutide; results are preclinical and may not translate to humans.
• Thu 27th Aug '26 · Reverse split: Artelo completed a 1-for-9 reverse stock split effective Aug 31, 2026, leaving about 547,774 shares outstanding, its second reverse split in the past year.
• Thu 20th Aug '26 · Litigation: Artelo amended its 10-Q to disclose a FINRA arbitration from Craft Capital Management seeking an $880,000 fee and warrants over a terminated engagement, with Artelo countersuing for fraudulent inducement.
• Tue 11th Aug '26 · ATM sale: Sold $354K net / 43K shares through its at-the-market program, as stated for Jul 1, 2026 to Aug 11, 2026.
• Tue 30th Jun '26 · ATM sale: Sold 16K shares through its at-the-market program.
• Tue 19th May '26 · Registration: Registered $75.00M of securities for sale on Form S-3.